Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Table 3 Effectiveness of a single oral dose of Credelio Plus against natural nematode infections in dogs presenting to European veterinary clinics

NNematode species	Sample^a	Treatment group^b	Number of dogs	Egg count per gram faeces
NNematode species	Sample^a	Treatment group^b	Number of dogs	Geometric Mean (GM)	GM % reduction	Number of dogs with zero eggs (%)	Effectiveness P-value^c
All nematode species	Pre-treatment	Credelio Plus Afoxolaner + MO	278 117	13.2 11.2	– –	– –	– –
All nematode species	Post-treatment	Credelio Plus Afoxolaner + MO	278 117	0.3 0.3	97.6 97.0	245 (88.2%) 99 (84.6%)	< 0.0001 (t₅₂₄ = 24.33) < 0.0001 (t₅₂₄ = 14.65)
Toxocara canis	Pre-treatment	Credelio Plus Afoxolaner + MO	54 19	16.4 8.0	– –	– –	– –
Toxocara canis	Post-treatment	Credelio Plus Afoxolaner + MO	54 19	0.5 0.4	97.2 95.3	48 (88.9%) 16 (84.2%)	< 0.0001 (t_79.3 = 4.36) < 0.0001 (t_79.3 = 9.70)
Ancylostoma caninum	Pre-treatment	Credelio Plus Afoxolaner + MO	109 42	11.2 9.9	– –	– –	– –
Ancylostoma caninum	Post-treatment	Credelio Plus Afoxolaner + MO	109 42	0.2 0.5	98.1 95.3	100 (91.7%) 35 (83.3%)	< 0.0001 (t₁₈₅ = 9.28) < 0.0001 (t₁₈₅ = 17.19)
Trichuris vulpis	Pre-treatment	Credelio Plus Afoxolaner + MO	176 80	9.8 9.7	– –	– –	– –
Trichuris vulpis	Post-treatment	Credelio Plus Afoxolaner + MO	176 80	0.2 0.1	97.8 98.5	156 (88.6%) 73 (91.2%)	< 0.0001 (t₃₄₀ = 12.79) < 0.0001 (t₃₄₀ = 18.57)

MO milbemycin oxime
^aPre-treatment sample collected once on Day 0; post-treatment sample collected on Day 8 (range 7–10)
^bSingle oral administration of Credelio Plus on Day 0 to provide a dose range of 0.75–1.56 mg/kg bodyweight MO and 20.0–41.5 mg/kg bodyweight lotilaner. Single oral dose of Nexgard Spectra on Day 0 to provide a dose range of 2.50–5.36 mg/kg bodyweight of afoxolaner and 0.50–1.07 mg/kg bodyweight of MO
^cEffectiveness P-value is the P-value for the within-treatment difference in least-square means

ISSN: 1756-3305